

# French Retail Market of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer (NSCLC): A Summary Report

**Health technology assessment results  
Target population  
Reimbursement prices  
2012-2016 market analysis**

Updated on March 28<sup>th</sup>, 2017

## Table of contents

<b>EGFR tyrosine kinase inhibitors marketed in France.....</b>	<b>2</b>
<b>Reimbursed indications and summary of health technology assessments.....</b>	<b>2</b>
Health technology assessment framework in France.....	2
TARCEVA <sup>®</sup> ( <i>erlotinib</i> ).....	3
IRESSA <sup>®</sup> ( <i>gefitinib</i> ).....	4
GIOTRIF <sup>®</sup> ( <i>afatinib</i> ).....	4
TAGRISSO <sup>®</sup> ( <i>osimertinib</i> ).....	5
<b>Epidemiology of lung cancer and EGFR-TKI target population.....</b>	<b>6</b>
Lung cancer incidence and mortality in France.....	6
Frequency of mutations in NSCLC.....	7
Target population and number of patients treated in 2014-2015.....	7
<b>Reimbursement prices.....</b>	<b>9</b>
Main principles of price setting and regulation in France.....	9
Distribution channels.....	10
Current EGFR TKI reimbursement prices and history of price reviews.....	10
<b>French EGFR TKI retail market analysis.....</b>	<b>12</b>
Market size and growth in 2012-2016.....	12
Market shares.....	13
Monthly reimbursed volumes dynamics in 2016.....	14
<b>List of references and links to the quoted sources.....</b>	<b>15</b>